Development of a reverse transcription quantitative polymerase chain reaction-based assay for broad coverage detection of African and Asian Zika virus lineages

Yang, Yang; Wong, Gary; Ye, Baoguo; Li, Shihua; Li, Shanqin; Zheng, Haixia; Wang, Qiang; Liang, Mifang; Gao, George F.; Liu, Lei; Liu, Yingxia; Bi, Yang

doi:10.1007/s12250-017-3958-y

“…Viral stock titration by 50% tissue culture infective dose (TCID 50 ) TCID 50 was measured as previously reported [50]. In brief, Vero cells in 96-well plates were grown to 80% con uence and infected with 10-fold serial dilutions of the stock SARS-CoV-2 (BetaCoV/Shenzhen/SZTH-003/2020, GISAID No.…”

Section: Cell Line and Drugsmentioning

confidence: 99%

FDA-approved Pralatrexate identified by virtual drug screening inhibits SARS-CoV-2 replication in vitro

Zhang

¹

,

Yang

²

,

Li

³

et al. 2020

Preprint

Self Cite

0

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic poses serious threats to the global public health and leads to an unprecedented worldwide crisis. Unfortunately, no effective drugs or vaccines are available till now. Since the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 is a promising therapeutic target, a deep learning and molecular simulation based hybrid drug screening procedure was proposed and applied to identify potential drug candidates targeting RdRp from 1906 approved drugs. Among the four selected FDA-approved drug candidates, Pralatrexate and Azithromycin were confirmed to effectively inhibit SARS-CoV-2 replication in vitro with EC50 values of 0.008µM and 9.453 µM, respectively. For the first time, our study discovered that Pralatrexate is able to potently inhibit SARS-CoV-2 replication with a stronger inhibitory activity than Remdesivir within the same experimental conditions. The paper demonstrates the feasibility of accurate virtual drug screening for inhibitors of SARS-CoV-2 and provides potential therapeutic agents against COVID-19.

show abstract

“…Viral stock titration by 50% tissue culture infective dose (TCID 50 ) TCID 50 was measured as previously reported 49 . In brief, Vero cells in 96-well plates were grown to 80% con uence and infected with 10-fold serial dilutions of the stock SARS-CoV-2 (BetaCoV/Shenzhen/SZTH-003/2020, GISAID No.…”

Section: Cell Line and Drugsmentioning

confidence: 99%

FDA-approved Pralatrexate and Azithromycin identified by virtual drug screening inhibit SARS-CoV-2 replication in vitro

Zhang¹,

Yang²,

Li³

et al. 2020

Preprint

Self Cite

1

0

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic poses serious threats to the global public health and leads to an unprecedented worldwide crisis. Unfortunately, no effective drugs or vaccines are available till now. Since the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 is a promising therapeutic target, a deep learning and molecular simulation based hybrid drug screening procedure was proposed and applied to identify potential drug candidates targeting RdRp from 1906 approved drugs. Among the four selected FDA-approved drug candidates, Pralatrexate and Azithromycin were confirmed to effectively inhibit SARS-CoV-2 replication in vitro with EC50 values of 0.008µM and 9.453 µM, respectively. For the first time, our study discovered that Pralatrexate is able to potently inhibit SARS-CoV-2 replication with a stronger inhibitory activity than Remdesivir within the same experimental conditions. The paper demonstrates the feasibility of accurate virtual drug screening for inhibitors of SARS-CoV-2 and provides potential therapeutic agents against COVID-19.

show abstract

“…A quantitative RT-PCR targeting E gene has been very recently developed that could detect all Asian and African lineages of ZIKV. This assay alleviates the disadvantage of earlier developed real-time PCR as they could not detect all strains of ZIKV and, moreover, this assay also showed a detection limit of 5 RNA transcript copies (Yang et al, 2017 ). A list of ZIKV detection assays is presented in Table 1 .…”

Section: Introductionmentioning

confidence: 97%

Advances in Diagnosis, Surveillance, and Monitoring of Zika Virus: An Update

Singh

¹

,

Dhama

²

,

Karthik

³

et al. 2018

View full text Add to dashboard Cite

Zika virus (ZIKV) is associated with numerous human health-related disorders, including fetal microcephaly, neurological signs, and autoimmune disorders such as Guillain-Barré syndrome (GBS). Perceiving the ZIKA associated losses, in 2016, the World Health Organization (WHO) declared it as a global public health emergency. In consequence, an upsurge in the research on ZIKV was seen around the globe, with significant attainments over developing several effective diagnostics, drugs, therapies, and vaccines countering this life-threatening virus at an early step. State-of-art tools developed led the researchers to explore virus at the molecular level, and in-depth epidemiological investigations to understand the reason for increased pathogenicity and different clinical manifestations. These days, ZIKV infection is diagnosed based on clinical manifestations, along with serological and molecular detection tools. As, isolation of ZIKV is a tedious task; molecular assays such as reverse transcription-polymerase chain reaction (RT-PCR), real-time qRT-PCR, loop-mediated isothermal amplification (LAMP), lateral flow assays (LFAs), biosensors, nucleic acid sequence-based amplification (NASBA) tests, strand invasion-based amplification tests and immune assays like enzyme-linked immunosorbent assay (ELISA) are in-use to ascertain the ZIKV infection or Zika fever. Herein, this review highlights the recent advances in the diagnosis, surveillance, and monitoring of ZIKV. These new insights gained from the recent advances can aid in the rapid and definitive detection of this virus and/or Zika fever. The summarized information will aid the strategies to design and adopt effective prevention and control strategies to counter this viral pathogen of great public health concern.

show abstract

Development of a reverse transcription quantitative polymerase chain reaction-based assay for broad coverage detection of African and Asian Zika virus lineages

Cited by 16 publications

References 36 publications

FDA-approved Pralatrexate identified by virtual drug screening inhibits SARS-CoV-2 replication in vitro

FDA-approved Pralatrexate identified by virtual drug screening inhibits SARS-CoV-2 replication in vitro

FDA-approved Pralatrexate and Azithromycin identified by virtual drug screening inhibit SARS-CoV-2 replication in vitro

Advances in Diagnosis, Surveillance, and Monitoring of Zika Virus: An Update

Contact Info

Product

Resources

About